Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 4/20 | 0.36 |
| ▸ | MAOA | P21397 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pregabalin SCHEMBL6345226 | 0.83 | CACNA2D1 (0.45) | GLRA1 | |
| SCHEMBL19168590 | 0.64 | MAOB (0.43) | MAPK1L3MBTL1PKMMAOBMAOA | |
| SCHEMBL21383038 | 0.63 | MAOB (0.67) | ALDH1A1HPGDMAOBMAOA | |
| SCHEMBL10657318 | 0.63 | MAOB (0.52) | L3MBTL1PKMMAOBMAOATDP1 | |
| SCHEMBL6216372 | 0.62 | MAOB (0.63) | LMNAHTTMAPK1TSHRGAA | |
| SCHEMBL25146420 | 0.60 | MAPK1 (0.53) | LMNAHTTMAPK1ALDH1A1HPGD | |
| SCHEMBL683595 | 0.60 | L3MBTL1 (0.58) | LMNAMAPK1ALDH1A1GAAGLRA1 | |
| SCHEMBL28078446 | 0.60 | GLRA1 (0.60) | LMNAHTTMAPK1ALDH1A1HPGD | |
| SCHEMBL683554 | 0.60 | RXRA (0.66) | LMNAGAAL3MBTL1MAOBMAOA | |
| SCHEMBL8370127 | 0.60 | LMNA (0.53) | LMNAHTTMAPK1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6924377-B2 | Process for preparing highly functionalized γ-butyrolactams and γ-amino acids | WARNER-LAMBERT COMPANY (US) | 2005-08-02 | — | — | US | disclosed |
| EP-1499583-A1 | PROCESS FOR PREPARING HIGHLY FUNCTIONALIZED Y-BUTYROLACTAMS AND Y-AMINO ACIDS | Warner-Lambert Company LLC (US) | 2005-01-26 | — | — | EP | disclosed |
| US-20030236415-A1 | Process for preparing highly functionalized gamma-butyrolactams and gamma-amino acids | BLAZECKA PETER G (CA) | 2003-12-25 | — | — | US | disclosed |
| US-20030225149-A1 | Process for preparing highly functionalized gamma-butyrolactams and gamma-amino acids | BLAZECKA PETER G (CA) | 2003-12-04 | — | — | US | disclosed |
| WO-2003093220-A1 | PROCESS FOR PREPARING HIGHLY FUNCTIONALIZED Y-BUTYROLACTAMS AND Y-AMINO ACIDS | WARNER-LAMBERT COMPANY LLC (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236415-A1 | Process for preparing highly functionalized gamma-butyrolactams and gamma-amino acids | GABRB2, GABRG2, GABRB1 | LMNA 2799/4885HTT 2722/4885MAPK1 2614/4885 |
| US-20030225149-A1 | Process for preparing highly functionalized gamma-butyrolactams and gamma-amino acids | GABRB2, GABRG2, GABRB1 | LMNA 2799/4885HTT 2722/4885MAPK1 2614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.